AbbVie (NY:ABBV)

262.99 +0.17 (+0.06%)

Delayed Quote Updated: 12:05 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

99 100 Next >

The $6 Billion Disconnect: Why Revolution Medicines (RVMD) Plunged 20% After Merck Talks Collapsed

January 26, 2026

The biotechnology sector has always been a high-stakes arena where clinical success can create multi-billion-dollar empires overnight, and a failed negotiation can erase a fifth of a company’s market...

Via Finterra

Topics Economy Initial Public Offering

The Best Dividend Stocks to Buy and Hold Forever ↗

January 26, 2026

These stocks offer highly attractive dividends and staying power.

Via The Motley Fool

Topics Intellectual Property

Stability Meets Scale: Why Johnson & Johnson is Poised for a Breakout 2026

January 23, 2026

As of January 23, 2026, Johnson & Johnson (NYSE:JNJ) finds itself at a historic crossroads. After spending much of 2025 navigating the "patent cliff" of its blockbuster drug Stelara and finalizing its...

Via MarketMinute

Topics Artificial Intelligence Bankruptcy Economy

AbbVie Seeks To Grow Obesity Drug Portfolio — Retail Touts Drugmaker As Big Competition To Lilly ↗

January 14, 2026

Via Stocktwits

Viking Therapeutics (VKTX) 2026 Deep Dive: Challenging the Obesity Duopoly

January 23, 2026

Date: January 23, 2026 Introduction In the high-stakes arena of metabolic medicine, few companies have generated as much speculative fervor and clinical awe as Viking Therapeutics (NASDAQ: VKTX). As of...

Via Finterra

Topics Intellectual Property

2 High-Yielding Dividend Stocks That Retirees Can Rely on for Recurring Income ↗

January 22, 2026

These stocks offer yields of more than double the S&P 500 average.

Via The Motley Fool

Topics Stocks

My Top 4 Stocks to Buy in Early 2026 ↗

January 22, 2026

These stocks offer impressive long-term upside with downside protection.

Via The Motley Fool

Topics Artificial Intelligence Economy

The Titan’s Balance: Johnson & Johnson Reaches Record Highs Amidst Legal Hurdles and Med-Tech Transformation

January 20, 2026

As the healthcare industry looks toward 2026, Johnson & Johnson (NYSE: JNJ) stands at a historic crossroads, reinforcing its reputation as the ultimate bellwether for the global healthcare sector. On...

Via MarketMinute

Topics Bankruptcy Lawsuit World Trade

1 Safe-and-Steady Stock on Our Watchlist and 2 We Find Risky

January 19, 2026

Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.

Via StockStory

The Best Healthcare Stocks to Buy With $5,000 in 2026 and Hold Forever ↗

January 19, 2026

All three of these healthcare giants are leaders in their niches.

Via The Motley Fool

Topics Artificial Intelligence

3 “Forever Stocks” to Hold When the Market Won’t Sit Still ↗

January 19, 2026

Via MarketBeat

The New Era of Johnson & Johnson: A 2026 Deep-Dive Research Feature

January 19, 2026

As of January 19, 2026, Johnson & Johnson (NYSE: JNJ) stands as a radically different enterprise than the one most investors recognized just three years ago. Following the successful spin-off of its...

Via Finterra

Topics Artificial Intelligence Bankruptcy Economy

Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever ↗

January 19, 2026

Income investors can rely on these stocks.

Via The Motley Fool

Topics Intellectual Property

The Smartest Dividend Stocks to Buy in 2026 With $1,000 Right Now -- Including Realty Income and AbbVie ↗

January 19, 2026

These stocks sport dividend yields ranging from 2.9% to 5.5%.

Via The Motley Fool

Could Buying This Stock Today Pay Off Big Over the Next 5 Years? ↗

January 18, 2026

This healthcare giant is a top pick for growth and dividend investors.

Via The Motley Fool

Topics Intellectual Property

AbbVie Call Options Spike 2,599%: Tracking the Big Bet ↗

January 16, 2026

Via MarketBeat

Genmab Reports Mixed Results From Late-Stage Trial Of Lymphoma Drug ↗

January 16, 2026

Epcoritamab demonstrated an improvement in progression-free survival in certain patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma, the company said.

Via Stocktwits

3 Absurdly Cheap Growth Stocks to Buy in 2026 ↗

January 15, 2026

These stocks could have plenty of upside for investors who invest in these businesses today.

Via The Motley Fool

Healthcare Titan Ascendant: Johnson & Johnson Hits All-Time Highs as It Navigates a New Political and Clinical Era

January 15, 2026

As of January 15, 2026, Johnson & Johnson (NYSE: JNJ) has emerged as the undisputed pacesetter of the healthcare sector, with its stock price surging to an all-time high of $218.53. This milestone...

Via MarketMinute

Topics Artificial Intelligence Bankruptcy Earnings

Nasdaq, S&P 500 Futures Edge Lower Ahead Of CPI, JPMorgan Earnings: Why MSFT, NVDA, ABBV, ABAT Are Also On Traders' Radar Today ↗

January 13, 2026

Retail sentiment remained mixed on Stocktwits, with a neutral view on SPY but growing bullishness around QQQ.

Via Stocktwits

Topics Artificial Intelligence Credit Cards ETFs

Revolution Medicines Dismisses Merck, Abbvie Buyout Talks While Analyst Say It Is Worth More Than $32B ↗

January 12, 2026

When asked about the company’s strategic transactions, CEO Mark Goldsmith said at a conference that the company has a policy of not commenting on rumors or speculation.

Via Stocktwits

The AI-Bio Convergence: Lilly and Nvidia Kick Off JPM26 with Landmark $1 Billion Alliance

January 12, 2026

The 44th Annual J.P. Morgan Healthcare Conference opened today in San Francisco with an intensity not seen in years, as the healthcare and technology sectors officially merged their futures. The...

Via MarketMinute

Topics Artificial Intelligence Intellectual Property

3 No-Brainer Dividend Stocks to Buy Right Now ↗

January 12, 2026

The decision about buying these dividend stocks is an easy one.

Via The Motley Fool

Topics Intellectual Property

This ETF Is Proof That the Healthcare Rebound Is Real ↗

January 11, 2026

Via MarketBeat

Topics ETFs

Eli Lilly Solidifies Immunology Dominance with $1.2 Billion Acquisition of Ventyx Biosciences

January 09, 2026

In a move that underscores the tightening intersection between metabolic health and systemic inflammation, Eli Lilly and Company (NYSE: LLY) officially announced on January 7, 2026, its definitive...

Via MarketMinute

2 Healthcare Stocks That Can Diversify a Tech-Heavy Portfolio ↗

January 09, 2026

Add some stability to your holdings with these healthcare giants.

Via The Motley Fool

Topics Economy Intellectual Property Lawsuit

MoonLake Immunotherapeutics Surges as FDA "De-Risks" Sonelokimab, Reigniting Multi-Billion Dollar Takeover Speculation

January 09, 2026

MoonLake Immunotherapeutics (NASDAQ: MLTX) shares have experienced a dramatic resurgence this week, climbing over 40% following a pivotal regulatory update that has effectively cleared the path for its...

Via MarketMinute

Topics Intellectual Property

The $20 Billion Question: Revolution Medicines Surges as Big Pharma Circles the Pan-RAS Leader

January 08, 2026

The first week of 2026 has set the biotech sector ablaze, with Revolution Medicines (NASDAQ: RVMD) finding itself at the epicenter of a high-stakes acquisition tug-of-war. Shares of the Redwood...

Via MarketMinute

Topics Intellectual Property

January 07, 2026

Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps...

Via StockStory

Ironwood Pharmaceuticals’ 2026 Guidance Shock Sparks a Major Re-Rating ↗

January 07, 2026

Via MarketBeat

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.